VIR: Vir Biotechnology, Inc. Stock

by  •  • Comments Off on VIR: Vir Biotechnology, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 758.40
Enterprise Value ($M) 535.46
Book Value ($M) 1,150.38
Book Value / Share 8.39
Price / Book 0.66
NCAV ($M) 794.03
NCAV / Share 5.79
Price / NCAV 0.96

Profitability (mra)
Return on Invested Capital (ROIC) -0.42
Return on Assets (ROA) -0.29
Return on Equity (ROE) -0.34

Liquidity (mrq)
Quick Ratio 8.71
Current Ratio 8.71

Balance Sheet (mrq) ($M)
Current Assets 1,042.46
Assets 1,398.81
Liabilities 248.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 74.20
Operating Income -552.17
Net Income -521.96
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -446.35
Cash from Investing 499.37
Cash from Financing 4.39

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
10-18 13G/A State Street Corp 4.10 -18.61

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURS
2024-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-14 57,186 497,818 11.49
2025-04-11 89,146 858,672 10.38
2025-04-10 185,124 942,299 19.65
2025-04-09 312,007 2,064,827 15.11

(click for more detail)

Similar Companies
UTHR – United Therapeutics Corporation VERV – Verve Therapeutics, Inc.
VIGL – Vigil Neuroscience, Inc. VOR – Vor Biopharma Inc.
VRTX – Vertex Pharmaceuticals Incorporated


Financial data and stock pages provided by
Fintel.io